Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International PLC is a British biopharmaceutical enterprise specializing in the discovery, acquisition, clinical development, and commercialization of innovative therapeutic medicines for patients suffering from debilitating autoinflammatory and cardiovascular diseases, prominently featuring commercialized products such as Arcalyst (rilonacept) approved for recurrent pericarditis and mavrilimumab evaluated in severe autoimmune conditions. The company conducts advanced clinical research in immunology and biopharmaceuticals. Its core business operations encompass clinical-stage drug development, biopharmaceutical commercialization, immunology research, and medical affairs management. Revenue is derived primarily from direct commercial product sales of Arcalyst across the United States. Kiniksa Pharmaceuticals International holds a leading market position in autoinflammatory therapeutics and recurrent pericarditis treatment. The company is headquartered in Hamilton, Bermuda, with operational headquarters in Braintree, Massachusetts, United States, and its Class A ordinary shares trade on the Nasdaq Global Select Market under the ticker KNSA.
5 of the funds FundTelligence covers report a position in Kiniksa Pharmaceuticals International.
- Legal name
- Kiniksa Pharmaceuticals International PLC
- Sector
- Health Care
- Country
- United Kingdom
- Funds holding it
- 5
Funds holding Kiniksa Pharmaceuticals International
- Aberdeen North American Smaller Companies Fund — Abrdn · 2.8 % (largest positions only, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.43 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.29 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.05 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)